Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 versus aflibercept in treatment-naive diabetic macular edema
2020-001062-11Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer in diabetic macular edema (DME) (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Mean change in best corrected visual acuity from baseline to Year 1. Started Oct 2020; status: terminated.
02
Drugs
tarcocimab tedromer
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2020-001062-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001062-11.